| 曹如冰，唐婧，艾超▲.帕博利珠单抗致不良反应文献分析[J].中国医药科学,2023,(20):117-120 基金项目: |
| 帕博利珠单抗致不良反应文献分析 |
| Literature analysis of adverse reactions induced by pembrolizumab |
| |
| DOI： |
| 中文关键词: 帕博利珠单抗；免疫检查点抑制剂；不良反应；文献分析 |
| 英文关键词:Pembrolizumab; Immune checkpoint inhibitor; Adverse reactions; Literature analysis |
| 作者 | 单位 | | 曹如冰，唐婧，艾超▲ | 清华大学附属北京清华长庚医院 清华大学临床医学院药学部，北京 102218 |
|
| 摘要点击次数: 312 |
| 全文下载次数: 308 |
| 中文摘要: |
| [摘要] 目的 分析帕博利珠单抗不良反应的发生情况及相关因素，以供临床安全用药参考。 方法 检索CNKI、万方、维普、PubMed、Embase、ScienceDirect数据库收载的帕博利珠单抗致不良反应的个案报道，检索时间为建库至2023年3月15日，对纳入病例信息资料，包括性别、年龄、原患疾病、用法剂量、ADR发生时间、累及系统、临床表现、预后和转归等进行回顾性分析。 结果 收集到帕博利珠单抗致ADR的案例报道171篇，共189例个案，其中60～79岁的患者（123例）占比最高；原患疾病以肺癌占比最高（75例）；给药后21 d和42～63 d内患者ADR发生频率较高；ADR表现以神经系统、呼吸系统为主；经治疗后，157例好转，32例死亡。 结论 帕博利珠单抗ADR潜伏期长，且可损害全身多个系统，即使在停用后较长一段时间内，临床上均应及时识别和发现ADR的早期信号，确保患者用药安全。 |
| 英文摘要: |
| [Abstract] Objective To analyze the occurrence and related factors of adverse reactions (ADR) of pembrolizumab, so as to provide reference for clinical safe medication. Methods Case reports of ADR caused by pembrolizumab collected in CNKI, Wanfang, VIP, PubMed, Embase and ScienceDirect databases were retrieved from the establishment of the database to March 15th, 2023. The effective information of the included cases, including the patient’s gender, age, original disease, dosage, ADR occurrence time, involved system, clinical manifestations, prognosis and outcome, were retrospectively analyzed. Results A total of 171 cases of ADR caused by pembrolizumab were collected, including 189 cases, and 123 cases were 60-79 years old. The highest proportion of primary diseases was lung cancer in 75 cases; The frequency of ADR in patients was relatively high within 21 days and 42-63 days after administration; The main manifestations of ADR were nervous system and respiratory system; After treatment, 157 cases alleviated and 32 cases died. Conclusion Pembrolizumab has a long latency of ADR, and it can damage many systems in the whole body. Even after stopping using it for a long time, early signs of ADR shall be both identified and found in time in clinic to ensure the safety of patients’ medication. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
.jpg)